#AANAM2026 ocrelizumab vs placebo in older and more disabled PPMS patients: delayed disability progression in EDSS and 9 hole peg. Better in younger, Active MS, and More disabled subgroups.
April 22, 2026 at 6:33 PM
#AANAM2026 ocrelizumab vs placebo in older and more disabled PPMS patients: delayed disability progression in EDSS and 9 hole peg. Better in younger, Active MS, and More disabled subgroups.
Join me, @drjmartindale.bsky.social and @rohitmarawar.bsky.social this afternoon at 2pm at Leadership University for our session on AI augmented leadership! #AANAM2026
You can find NDEC all over the conference today! Join a session or two and #AANAM2026 day 2!
April 19, 2026 at 2:12 PM
Join me, @drjmartindale.bsky.social and @rohitmarawar.bsky.social this afternoon at 2pm at Leadership University for our session on AI augmented leadership! #AANAM2026
As #AANAM2026 wraps up, NHN is proud to have connected with and engaged so many through our work.
Grateful to all who attended our sessions, explored our posters, and supported us, especially AAN for the DEI Innovator Grant.
Onward to more impact!
Adieu, Chicago ✨
#Neurology
Grateful to all who attended our sessions, explored our posters, and supported us, especially AAN for the DEI Innovator Grant.
Onward to more impact!
Adieu, Chicago ✨
#Neurology
April 23, 2026 at 4:05 AM
As #AANAM2026 wraps up, NHN is proud to have connected with and engaged so many through our work.
Grateful to all who attended our sessions, explored our posters, and supported us, especially AAN for the DEI Innovator Grant.
Onward to more impact!
Adieu, Chicago ✨
#Neurology
Grateful to all who attended our sessions, explored our posters, and supported us, especially AAN for the DEI Innovator Grant.
Onward to more impact!
Adieu, Chicago ✨
#Neurology
Had a great #AANAM2026. while I was not involved in most of these, I have to brag about Creighton University School of Medicine students Chloe Cohan and Mawj Alzakar, both of whom had abstracts, and BNI resident Vishnu Dantu and fellow Maria Garcia-Dominguez who each had neuroimmunology abstracts.
April 22, 2026 at 11:52 PM
Had a great #AANAM2026. while I was not involved in most of these, I have to brag about Creighton University School of Medicine students Chloe Cohan and Mawj Alzakar, both of whom had abstracts, and BNI resident Vishnu Dantu and fellow Maria Garcia-Dominguez who each had neuroimmunology abstracts.
Exciting results in the clinical trial Plenary at #AANAM2026.
the first positive phase 3 trial in MOGAD! satralizumab significantly reduced relapse rates in relapsing MOGAD compared to placebo with stable baseline open label immunosuppression allowed. IVSM use & MRI also favored satralizumab.
the first positive phase 3 trial in MOGAD! satralizumab significantly reduced relapse rates in relapsing MOGAD compared to placebo with stable baseline open label immunosuppression allowed. IVSM use & MRI also favored satralizumab.
April 21, 2026 at 4:08 PM
Exciting results in the clinical trial Plenary at #AANAM2026.
the first positive phase 3 trial in MOGAD! satralizumab significantly reduced relapse rates in relapsing MOGAD compared to placebo with stable baseline open label immunosuppression allowed. IVSM use & MRI also favored satralizumab.
the first positive phase 3 trial in MOGAD! satralizumab significantly reduced relapse rates in relapsing MOGAD compared to placebo with stable baseline open label immunosuppression allowed. IVSM use & MRI also favored satralizumab.
#AANAM2026 non-inferiority study of fenebrutinib vs ocrelizumab in PPMS. fenebrutinib is non-inferior to ocrelizumab BUT the inactive PPMS population differs from the original ORATORIO trial, so non-inferior to what? I don't have great confidence in ocrelizumab's efficacy in this population.
April 22, 2026 at 7:11 PM
#AANAM2026 non-inferiority study of fenebrutinib vs ocrelizumab in PPMS. fenebrutinib is non-inferior to ocrelizumab BUT the inactive PPMS population differs from the original ORATORIO trial, so non-inferior to what? I don't have great confidence in ocrelizumab's efficacy in this population.
Exciting results in the clinical trial Plenary at #AANAM2026.
First, phase 2 trial on neuro protection in acute optic neuritis. Privosegtor 3mg/kg dosed within 12 days of symptoms WITH concurrent IVSM showed benefit in low contrast visual acuity and OCT. notably aqp4+ excluded.
First, phase 2 trial on neuro protection in acute optic neuritis. Privosegtor 3mg/kg dosed within 12 days of symptoms WITH concurrent IVSM showed benefit in low contrast visual acuity and OCT. notably aqp4+ excluded.
April 21, 2026 at 4:03 PM
Exciting results in the clinical trial Plenary at #AANAM2026.
First, phase 2 trial on neuro protection in acute optic neuritis. Privosegtor 3mg/kg dosed within 12 days of symptoms WITH concurrent IVSM showed benefit in low contrast visual acuity and OCT. notably aqp4+ excluded.
First, phase 2 trial on neuro protection in acute optic neuritis. Privosegtor 3mg/kg dosed within 12 days of symptoms WITH concurrent IVSM showed benefit in low contrast visual acuity and OCT. notably aqp4+ excluded.
You can find NDEC all over the conference today! Join a session or two and #AANAM2026 day 2!
April 19, 2026 at 1:56 PM
You can find NDEC all over the conference today! Join a session or two and #AANAM2026 day 2!